The expression of immediate early response 3 (IER3), a protein with a short half-life, is rapidly induced by various cellular stimuli. We recently reported that IER3 induces the apoptosis of cervical cancer cells and that its expression is downregulated in patients with cervical cancer. However, the molecular mechanism involved in the rapid degradation of IER3 remains unknown. Here, we demonstrate that MDM2 is an E3 ligase that interacts with IER3 and promotes its ubiquitination, followed by proteasomal degradation. Polyubiquitination of the conserved lysine 60 of IER3 is essential for its degradation. In addition, four and a half LIM domains protein 2 (FHL2) binds to both IER3 and MDM2, allowing for efficient MDM2-mediated IER3 degradation by facilitating an association between MDM2 and IER3. Moreover, IER3 induces cell cycle arrest in cervical cancer cells and its activity is further enhanced in cells in which FHL2 or MDM2 was silenced, thereby preventing IER3 degradation. The E6 and E7 oncoproteins of human papilloma virus 18 regulated IER3 expression. FHL2 expression was significantly higher in the squamous epithelium of cervical carcinoma tissues than in non-cancerous cervical tissues, whereas cervical carcinoma expression of IER3 was downregulated in this region. Thus, we determined the molecular mechanism responsible for IER3 degradation, involving a ternary complex of IER3, MDM2 and FHL2, which may contribute to cervical tumor growth. Furthermore, we demonstrated that FHL2 serves as a scaffold for E3 ligase and its substrate during the ubiquitination reaction, a function that has not been previously reported for this protein.
INTRODUCTION
Regulation of protein degradation is a fundamental homeostasis mechanism that controls protein levels in cells. 1 In eukaryotes, intracellular protein degradation is achieved by ubiquitin-mediated proteasomal destruction and lysosome-mediated proteolysis. 2 The ubiquitin-proteasomal pathway constitutes a selective process in which the concerted actions of an ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin-protein ligase (E3) lead to the attachment of ubiquitin to the lysine residues of substrate proteins, and the product is then recognized by the 26S proteasome. 3, 4 During this process, E3 ligases play a central role as they recognize specific protein substrates and catalyze ubiquitin transfer. 5 MDM2 is a RING finger family E3 ubiquitin ligase proto-oncogene known for mediating the degradation of the tumor-suppressor p53. 6, 7 The expression of immediate early response gene 3 (IER3) is rapidly induced by various cellular stimuli such as DNA damage, growth factors, cytokines and viral infection. 8, 9 IER3 regulates cellular apoptosis, proliferation, DNA repair, differentiation and inflammation. [10] [11] [12] [13] [14] We recently reported that IER3 induces apoptosis in cervical cancer cells and its expression is downregulated in tissues from patients with cervical carcinoma. 15 IER3 is known to have a short half-life and its degradation can be prevented by a proteasomal inhibitor. 16 However, the molecular mechanism involved in the regulation of IER3 degradation remains unknown.
Four and a half LIM domains protein 2 (FHL2), also known as DRAL, belongs to the four and a half LIM domains protein family. 17, 18 FHL2 is a multifunctional protein involved in a wide range of cellular processes, including the regulation of gene expression, cell survival, proliferation, differentiation, adhesion and motility. [19] [20] [21] Because of its structural nature, FHL2, consisting of multiple LIM motifs that serve as protein-binding sites, interacts with diverse types of proteins and assembles multi-protein complexes. 20, 22 Cervical cancer is the second leading cause of cancer-related death in women worldwide. 23 Infection with human papilloma viruses (HPVs), including HPV 16 and 18, is the major etiology for cervical malignancy. 24, 25 Viral E6 and E7 from high-risk HPVs are two critical oncoproteins for cervical cancer development by deregulation of cell proliferation, apoptosis and genome instability. 26 Although little is known regarding the role of FHL2 in cervical cancer, its interaction with E6 and E7 oncoproteins has been reported. 27, 28 In this study, we revealed the signaling mechanism involved in IER3 degradation. We demonstrated that IER3 undergoes MDM2-mediated polyubiquitination followed by proteasomal degradation, in which FHL2 acts as a scaffold that facilitates the association of MDM2 to IER3. In addition, we found that IER3 induces cell cycle arrest in cervical carcinoma cells, which is further increased in either FHL2-or MDM2-depleted cells. Furthermore, a significant upregulation of FHL2 and downregulation of IER3 in the squamous epithelium of cervical carcinoma tissues suggest that the FHL2-mediated IER3 degradation could be implicated in the development of cervical carcinoma.
RESULTS

FHL2 interacts with IER3
To understand the intracellular molecular mechanism involved in the regulation of IER3, yeast two-hybrid screening of a human ovarian cDNA library was performed using the full-length human IER3 as the bait. Among isolated interacting clones, three were identified as FHL2 and the specific interaction between IER3 and FHL2 was confirmed in the yeast two-hybrid system (Figure 1a) . The in vivo interaction of these two proteins was verified by immunoprecipitation followed by western blot analysis after overexpression in 293T cells (Figures 1b and c) . In addition, the association of endogenous FHL2 and IER3 proteins was observed in HeLa cervical carcinoma cells (Figure 1d ). Immunofluorescence confocal microscopic analysis showed that endogenous FHL2 and IER3 were co-localized in the cytoplasm of HeLa cells (Figure 1e ).
The association of FHL2 and IER3 is mediated by LIM3 and 4 domains and the PEST (proline, glutamic acid, serine, threonine)-rich region To define the binding domain that mediates the interaction of FHL2 and IER3, we generated plasmids encoding HA-tagged full-length and deleted mutant forms of FHL2 (Figure 2a ). These constructs were co-transfected with glutathione sepharose (GST)-tagged IER3 into HeLa cells and then immunoprecipitated. As shown in Figure 2b , FHL2 mutants lacking the LIM4 and/or LIM3 domains at the C-terminal end (ΔC1 and ΔC2) failed to bind to IER3, indicating that the these LIM domains are involved for their association. We also produced plasmids encoding GSTtagged full-length and serially deleted mutants of IER3 (Figure 2c ). The IER3 mutant with deleted sequences from amino acid 26 to 50 (Δ2) did not interact with FHL2, suggesting that this PEST-rich region mediates the binding to FHL2 (Figure 2d ). Furthermore, we generated additional mutants of FHL2 (ΔN3 and ΔN4) and IER3 (PEST) to determine whether the minimal binding motives mapped from Figures 2b and d are sufficient for their interaction. As shown in Figure 2e , the LIM 3 and 4 domains of FHL2 and the PEST-rich region (amino acids 26-55) of IER3 were sufficient for their association.
FHL2 stimulates ubiquitination-mediated proteasomal degradation of IER3 To investigate the functional role of the association between FHL2 and IER3, these two proteins were overexpressed in HeLa cells. The IER3 protein level was decreased by FHL2 overexpression (Figure 3a) . FHL2 knockdown using specific small interfering RNAs (siRNAs) increased the levels of endogenous IER3 (Figure 3b and Supplementary Figure 1a) as well as its stability (Figure 3c ). In contrast, the IER3 mRNA level was not affected by the modulation of FHL2 expression, as determined by quantitative real-time PCR analysis (Supplementary Figure 2) . Cellular proteins are mainly degraded via the ubiquitin-mediated proteasomal and lysosomal pathways. 2 Thus, we determined the degradation pathway involved in FHL2-induced downregulation of IER3 expression using inhibitors of the two degradation pathways. FHL2-induced downregulation of IER3 was completely blocked by the proteasomal inhibitor, MG132, but not by the lysosomal inhibitor, chloroquine (Figure 3d ). In addition, IER3 underwent ubiquitination, which was augmented by FHL2 overexpression, whereas the FHL2 mutant lacking IER3-binding capacity (ΔC2) failed to increase IER3 ubiquitination (Figure 3e ). The attenuation of IER3 ubiquitination in FHL2-depleted cells further supports that FHL2 stimulates IER3 polyubiquitination in cells (Figure 3f) . A decrease in endogenous IER3 ubiquitination was also confirmed in FHL2 knockdown HeLa cells (Figure 3g ). Lysine (K) 60 residue is the primary ubiquitination site on IER3 Human IER3 possesses only two lysine residues. Comparative sequence analysis of IER3 orthologs in mammalian species revealed two conserved lysine residues at the amino-acid positions 60 and 84 ( Figure 4a ). We generated two IER3 mutants in which the K residues were replaced with arginine (R) residues, K60R and K84R, and compared their protein stabilities. Although the levels of both wildtype (WT)-IER3 and the K84R mutant increased in the presence of MG132, the K60R mutant protein was present at a higher basal level, which was not affected by the proteasome inhibitor (Figure 4b) . Accordingly, the levels of WT and K84R IER3 were clearly increased by FHL2 knockdown, whereas the level of the K60R mutant did FHL2 promotes MDM2-mediated IER3 degradation H Jin et al not change (Figure 4c ). Moreover, FHL2 overexpression failed to decrease the level of K60R IER3 (Figure 4d ). Consistently, K60R IER3 was resistant to ubiquitination, even after forced expression of FHL2 (Figure 4e ). This lack of ubiquitination was not a consequence of the inability of IER3 to interact with FHL2, as these proteins showed efficient binding (Figure 4e ).
IER3 is a novel substrate of MDM2 E3 ligase To identify the specific E3 ubiquitin ligase targeting IER3, the interaction of E3 ligases with IER3 was examined by immunoprecipitation. We found that IER3 associated with MDM2, but not with other E3 ligases such as SKP2 and β-TrCP (Figure 5a ). Immunoblot analysis of HeLa cell lysates also showed that MDM2 overexpression prominently decreased the IER3 level (Figure 5a) . A direct interaction between IER3 and MDM2 was also demonstrated by immunoprecipitation using purified recombinant proteins (Figure 5b and Supplementary Figure 3a) . To determine the binding region, truncated MDM2 mutants were generated ( Figure 5c ). Immunoprecipitation results shows that the ring domain of MDM2 mediated its interaction with IER3, as the ΔC1 and ΔC2 mutants failed to associate with IER3 ( Figure 5d ). FHL2 stimulates MDM2-mediated ubiquitination of IER3 by forming a ternary complex Next, we investigated the inter-regulatory mechanism that promotes IER3 degradation by FHL2 and MDM2. FHL2-mediated downregulation of IER3 was prevented by silencing of MDM2 (Figure 6a ), indicating that the stimulating effect of FHL2 on IER3 proteasomal degradation involves the action of MDM2. Similarly, MDM2 failed to downregulate IER3 when FHL2 was silenced (Figure 6b ), suggesting that FHL2 is necessary for MDM2 activity to degrade IER3. We found that FHL2 also directly interacts with MDM2 as determined by the in vitro pull-down assay using recombinant FHL2 and GST-MDM2 proteins ( Figure 6c ). Their interaction was mediated by the LIM2 domain of FHL2 ( Figure 6d ) and the region (amino acids 101-234) between the p53-binding motif and acidic domain of MDM2 ( Figure 6e ). This ternary complex formation by endogenous proteins was further confirmed in a two-step immunoprecipitation experiment (Supplementary Figure 5a) .
To address how FHL2 stimulates MDM2-induced IER3 degradation, the effect of FHL2 on the binding capacity of MDM2 to IER3 was determined by immunoprecipitation. FHL2 overexpression enhanced the interaction between MDM2 and IER3 by more than 2.5-fold, whereas overexpression of the FHL2 mutant lacking the ability to bind IER3 (ΔC2) did not affect the strength of the MDM2-IER3 interaction (Figure 6f ). In addition, the interaction between MDM2 and IER3 was decreased in FHL2 knockdown HeLa cells (Figure 6g ), indicating that FHL2 allows for the efficient binding of MDM2 to IER3. In addition, the formation of an endogenous ternary complex of FHL2-IER3-MDM2 in HeLa cells (Figure 6h and Supplementary Figure 5b) and a clearly increased in vitro association between MDM2 and IER3 in the presence of FHL2 recombinant protein (Figure 6i and Supplementary Figure 3b) were confirmed. Furthermore, the in vitro ubiquitination assay results confirmed that MDM2-mediated ubiquitination of IER3 was augmented by the addition of FHL2 protein (Figure 6j ), and ubiquitinated IER3 was decreased by knockdown of either FHL2 or MDM2 (Supplementary Figure 6) . FHL2 and MDM2 regulate IER3-induced anti-proliferative activity FHL2 overexpression promoted cell cycle progression to the S and G 2 /M phases, whereas the overexpression or knockdown of IER3 induced G 0 /G 1 phase arrest or cell cycle progression, respectively (Figures 7a and b) . In addition, the knockdown of either FHL2 or MDM2, which increases IER3 stability, decreased the cell population in the S phase. The IER3-induced inhibitory activity on the cell cycle progression to S phase was further increased in FHL2-or MDM2-silenced cells (Figure 7c ). Simultaneously, consistent effects on cell proliferation were also observed by measuring 5′-bromo-2′-deoxyuridine-positive cells (Supplementary Figures 7a and b) . Moreover, the regulatory roles of MDM2 and FHL2 on IER3 was further determined using mouse knockout cells of MDM2 ; Figure 7d ). Accordingly, IER3 was still able to inhibit the proliferation of these p53-null cells (Figure 7e ). This p53-independent regulation of IER3 was further confirmed in p53-knockdown HeLa cells (Supplementary Figure 7c) , in which MDM2-mediated IER3 expression and the anti-proliferative function of IER3 was dependent on MDM2 but independent of p53.
As the E6 and E7 oncoproteins are critical in cervical cancer development, E6 and E7 were knocked down in HeLa cells, and the levels of IER3, FHL2 and MDM2 were assessed. As shown in Figures 7f and g, E6 knockdown resulted in the upregulation of MDM2 with concomitant downregulation of IER3 protein, whereas E7 knockdown induced the downregulation of IER3 without affecting the MDM2 level. The results of quantitative real-time PCR analysis suggest that E7 knockdown-induced IER3 downregulation occurs at the transcriptional level (Supplementary Figure 8) .
The squamous epithelium of cervical carcinoma tissues exhibits inverse expression profiles for FHL2 and IER3 We further examined the expression profile of FHL2, IER3 and MDM2 in human cervical carcinoma tissues. For this purpose, a tissue microarray (TMA) containing cervical carcinoma and noncancerous cervical tissues was constructed (Supplementary Table 1 and Supplementary Figures 9b and d) . In contrast, no significant difference was observed in term of MDM2 expression between the two groups ( Figure 8a and Supplementary Figures 9c and d) .
Representative images of IHC of each protein in higher magnification are presented in Supplementary Figure 9d . The receiver operating characteristic (ROC) curve analysis of FHL2 immunostaining showed perfect specificity (1.0) and sensitivity (1.0) to cervical carcinoma tissues in the TMA training set (Figure 8b and Supplementary Table 2 ). In addition, the ROC for IER3 immunostaining showed a good specificity (0.92) and sensitivity (0.86-0.78) to discriminate normal cervix and cervical carcinoma tissues, whereas MDM2 immunostaining exhibited no meaningful value (Figure 8b  and Supplementary Table 2 ). ROC curve analysis of the proportion score (PS), intensity score (IS) and total scores of the TMA assay results, calculated as the sum of the PS (0-5) of positive cells and the IS (0-3 scales) of immunostaining, yielded area under the curves similar to those determined from the percentage of positive cells (Supplementary Table 2 ). Based on our findings, we proposed that the molecular regulation of IER3 degradation involves the interaction of FHL2 and MDM2 proteins, leading to the ubiquitinationmediated proteasomal degradation of IER3 (Figure 8c ).
DISCUSSION
Considering that IER3 is an immediate early response protein having a short half-life, cells must possess a specific and rapid degradation machinery capable of such a tight control of IER3 expression. However, mechanisms underlying IER3 degradation remain unknown. Here, for the first time, we demonstrate that IER3 degradation is regulated by a multimeric protein complex that incorporates FHL2, MDM2 and IER3. The ubiquitin-mediated proteasome pathway mediates the targeted degradation of most short-lived proteins in eukaryotic cells by tagging proteins on lysine residues with ubiquitin. 2 In this study, we identified MDM2 is the E3 ligase for IER3 and demonstrated that IER3 undergoes MDM2-mediated ubiquitination on the highly conserved K60 residue followed by proteasomal degradation. The LIM domain consists of two zinc finger motifs, which mediate protein-protein interactions.
22 FHL2 pleiotropic functions are likely attributable to the presence of multiple LIM domains. Here, we identified two novel FHL2-interacting proteins, IER3 and MDM2, which form a ternary complex. Of particular interest, FHL2 was necessary for the interaction of MDM2 ligase with IER3. Thus, we defined a unique and critical role of FHL2 in the regulation of IER3 protein degradation in which FHL2 is likely facilitating the efficient ubiquitination of IER3 through positioning IER3 and MDM2 in close proximity by binding to both proteins. These observations indicate that FHL2 functions as a scaffold or an adaptor protein required to convey the effective signal transduction involved in IER3 degradation.
The transforming activity of HPV infection is largely mediated by the HPV-derived E6 and E7 oncoproteins that dysregulate crucial signaling pathways. 24, 29 The E6 protein binds to E6-associated protein and degrades p53, a well-known tumor suppressor, leading to increased cell cycle progression and inhibited apoptosis followed by the accumulation of DNA-damaged cells. 29, 30 The E7 protein inactivates the tumor-suppressor family of retinoblastoma proteins, inducing uncontrolled activation of E2F transcriptional factor, consequently stimulating cell cycle progression. [31] [32] [33] In the present study, we found that both E6 and E7 regulate IER3 expression in HPV-infected cells. IER3 downregulation induced by E6 depletion is likely the outcome of robust expression of MDM2, which facilitates IER3 degradation, whereas its downregulation by E7 depletion is likely associated with the transcriptional regulation of IER3 mRNA. Although additional studies exploring the precise mechanism are required, this finding further supports the tumor-suppressive role of IER3 in HPV-mediated carcinogenesis.
We previously reported that the p53 family member TAp73β is a specific transcriptional activator of IER3 in cervical cancer cells and defective expression of TAp73β in cervical carcinoma contributes to the downregulation of IER3 transcription. 15 The current findings showing the FHL2-mediated enhanced IER3 protein degradation in cervical cancer cells and the inverse expression profiles of FHL2 and IER3 in cervical cancer tissues indicate the presence of an IER3 downregulation machinery at its protein level as well. Taken together, deficient expression of IER3 in cervical carcinoma and its critical role as an effective inducer of both apoptotic cell death 15 and cell cycle arrest in cervical carcinoma cells (Figure 7) imply that IER3 is a crucial molecule, which possibly functions as a tumor suppressor during cervical cancer development. Therefore, based on these observations, we postulate that the inhibition of IER3 activity, resulting from IER3 downregulation at both the transcriptional and post-translational level, likely contributes to the growth of cervical carcinoma. In addition, our study demonstrates that IER3 expression is under a tight regulatory control to maintain cellular homeostasis and its perturbation may be linked to cervical tumor development and progression.
Cumulative evidence suggests that FHL2 function depends on the cell type and the interacting proteins.
34 FHL2 expression profile also varies depending on the cancer type, it can be overexpressed or downregulated. 34 In addition, FHL2 opposite activities, that is, the induction or inhibition of apoptosis and proliferation, have been reported in different cell types. [35] [36] [37] [38] [39] Likewise, dual proapoptotic and antiapoptotic functions of IER3 that depend on the cellular context and contrasting IER3 expression profiles have been reported depending on the cancer type. 40 Although the underlying cellular mechanism that accounts for these differences is still elusive, the interplay between FHL2 and IER3 may be implicated in these cell context-dependent contrasting outcomes.
Disturbed protein degradation is involved in multiple pathophysiological conditions, including cancer. 41, 42 Proteasome inhibitors such as bortezomib have emerged as new chemotherapeutic agents. 43, 44 Targeting and intervening with cell-type-specific molecules that regulate proteasomal degradation such as FHL2 would be an attractive and beneficial strategy to minimize side effects and, thus, the future application of FHL2 modulatory approaches is warranted. In addition, FHL2 immunostaining can serve as a good diagnostic tool for cervical cancer as it showed perfect specificity and sensitivity in the TMA (Figure 8b ). In summary, we demonstrated a molecular network involved in the proteasome-mediated IER3 degradation, involving the ternary complex, FHL2-MDM2-IER3. This protein complex, where FHL2 has a key intermediary role, may be implicated in the development of cervical carcinoma.
MATERIALS AND METHODS
Mammalian cell culture and reagents
HeLa (American Type Culture Collection, Manassas, VA, USA), SiHa (Korean Cell Line Bank, Seoul, South Korea) and 293T (American Type Culture Collection) cells were cultured in Dulbecco's modified Eagle medium containing 10% fetal bovine serum and 1% penicillin-streptomycin. Cells were grown in an incubator at 37°C with 5% CO 2 . Reagents used for cell culture were purchased from Caisson (Caisson, North Logan, UT, USA). The proteasome inhibitor MG132 was purchased from BioVison (Mountain View, CA, USA). Bis(sulfosuccinimidyl)suberate (BS3), a crosslinker, was purchased from Thermo Scientific (Rockford, IL, USA). Other agents, including chloroquine, cycloheximide and thrombin were purchased from Sigma-Aldrich (St Louis, MO, USA) unless otherwise indicated.
Plasmid constructs
The FHL2 WT and mutant plasmids were produced by PCR amplification using the following primers: FHL2 WT-F (5′-ACGGAATTCAAATGACTGAGCG CTTTGAC-3′) with FHL2 WT-R (5′-TTACTCGAGTCAGATGTCTTTCCCACA GT-3′); FHL2 WT-F with FHL2 nC1-R (5′-CATCTCGAGTTAGTCACAGAAGCAG TTCAGGCA-3′); FHL2 WT-F with FHL2 nC2-R (5′-CATCTCGAGTTATTTCTCAT AGCAGGGCACACA-3′); FHL2 nN1-F (5′-ACGGAATTCAAATGTTCGCCAACAC Yeast two-hybrid assay Yeast two-hybrid screening was performed according to a previous study. 47 Immunoprecipitation and immunoblot analysis HeLa cells were transfected with the indicated plasmids as well as with small interference nucleotides (siRNAs) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Twenty-four hours after transfection, cell lysates were prepared for immunoprecipitation with GST (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) beads or Dynabeads protein G (Invitrogen) according to manufacturer's instructions. After incubation, the samples were boiled and subjected to SDSpolyacrylamide gel electrophoresis for immunoblotting with the respective antibodies. The protein signal on the membranes was detected using a ChemiDoc XRS+ System Imager (Bio-Rad Laboratories, Hercules, CA, USA) and the intensity of each band was quantified using Quantity One software (Bio-Rad Laboratories). The following antibodies were used in this study: mouse anti-FHL2 (11-134; MBL International, Woburn, MA, USA), mouse anti-c-Myc (631206; Clontech), rabbit anti-HA (H6908) and mouse anti-FLAG M2 (F1804; Sigma-Aldrich), mouse anti-ubiquitin (sc-8017), rabbit anti-IER3 (sc-33171), mouse anti-MDM2 (sc-965), mouse anti-HPV18 E6 (sc-365089), mouse anti-HPV18 E7 (sc-365035), mouse anti-p53 (sc-126), rabbit anti-GFP (sc-8334) and rabbit anti-GAPDH (sc-25778; all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-GST (2624) and rabbit anti-FLAG (2638) antibodies (Cell Signaling, Danvers, MA, USA).
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Immunofluorescence analysis
The immunofluorescence analysis was performed as previously described. 48 
RNA interference
Small-interfering RNA (siRNA) target sequences against FHL2, MDM2, IER3, p53, HPV18 E6 and HPV18 E7 were 5′-AACUGCUUCUGUGACUUGU-3′ (FHL2 #1), 5′-CGAAUCUCUCUUUGGCAAG-3′ (FHL2 #1), 5′-GAAGUUAUUAA AGUCUGUU-3′ (MDM2 #2), 5′-CCAGCCAAAAGGCUUCUCUUU-3′ (IER3 #1), 5′-UUCACCUUCGACCCUCUCC-3′ (IER3 #2), 5′-CACUACAACUACAUGUGU A-3′ (p53), 5′-CUAACUAACACUGGGUUAU-3′ (HPV18 E6) and 5′-CCACCAAC GUCACACAAUGU-3′ (HPV18 E7). MDM2 siRNA (#1) was purchased from Bioneer (Daejeon, South Korea). The control siRNA sequence used was 5′-CCUACGCCACCAAUUUCGU-3′. The sense and antisense oligonucleotides were annealed in the presence of the annealing buffer (Bioneer).
RNA extraction and real-time PCR RNA was extracted from transfected HeLa cells using TRIzol reagent (Invitrogen). The extracted RNA was analyzed by real-time PCR as described previously. 15 The nucleotide sequences of primers used for real-time PCR (Bioneer) were IER3-F (5′-CAGCCGCAGGGTTCTCTAC-3′), IER3-R (5′-GATCTGGCAGAAGACGATGGT-3′), GAPDH-F (5′-AGGGGCCATCCACAG TCTT-3′) and GAPDH-R (5′-AGCCAAAAGGGTCATCATCTCT-3′).
Ubiquitination assay
The in vivo and in vitro ubiquitination assays were performed as previously described. 46, 49 Recombinant protein purification
The pGEX4T1-FHL2 plasmid was expressed in Rosetta 2 (DE3) competent cells, a derivative strain of Escherichia coli strain BL21 (EMD Millipore, Billerica, MA, USA). Cells were cultured in Luria-Bertani medium and selected with ampicillin (100 μg/ml) and chloramphenicol (34 μg/ml). The cells were grown in a shaking incubator at 37°C until OD 600 = 0.5-0.6 and then supplemented with 100 μM isopropyl β-D-thiogalactoside (SigmaAldrich) dissolved in the Luria-Bertani medium for 2 h at 23°C. Thereafter, the cells were harvested and washed twice with cold PBS, resuspended in PBS containing a protease inhibitor cocktail and lysed by sonication. The separated supernatant from lysates was linked to GST beads and incubated overnight at 4°C. Beads were washed and the GST-bound proteins were eluted with 10 mM reduced glutathione. GST-IER3 was purified from mammalian cells through transfection of 293T cells with pCDNA3.1 GST-IER3 plasmids. Twenty-four hours after the transfection, the cells were lysed in radio-immunoprecipitation assay buffer containing 1 mM Na 3 VO 4 , 10 mM NaF and protease inhibitor cocktail. The supernatant was then separated from 293T cell lysates and incubated with GST beads overnight at 4°C. Beads were washed and GST-bound proteins were eluted with 10 mM reduced glutathione in 50 mM Tris (pH 8.0). The GST tag from the GST-MDM2 and GST-FHL2 proteins were removed by incubation with 100 U/ml thrombin for 16 h at 4°C.
Two-step co-immunoprecipitation
Ten dishes of HeLa cells (4-5 × 10 6 cells/100-mm dish) were lysed with NP-40 lysis buffer and centrifuged. The supernatant was incubated with BS3-crosslinked anti-IER3-Dynabeads protein G overnight at 4°C. The first immunoprecipitated samples were washed with precooled PBS-T three times, and the IER3-linked protein complex was eluted with 0.1 M glycine buffer (pH 2.0) for 1-2 min and immediately neutralized in 1 M Tris buffer (pH 10.0). The second round of immunoprecipitation was performed by incubation of the first elute with crosslinked anti-MDM2-Dynabeads protein G overnight at 4°C.
Analysis of cell cycle by flow cytometry
The cell cycle analysis was performed as previously described.
50
5′-Bromo-2′-deoxyuridine cell proliferation assay
The 5′-bromo-2′-deoxyuridine cell proliferation assay was performed using the 5′-bromo-2′-deoxyuridine labeling and detection kit III (Roche) according to the manufacturer's instructions.
Human tissue sampling and TMA construction Table 1 ). The median age of the patients was 52.5 years, with the ages ranging from 31 to 75 years. The control group included duplicate cores of paraffin-embedded samples of normal cervical tissues obtained from 20 patients (median = 46.5 years, range = 42-69 year), who were diagnosed with other non-cancerous diseases at the same hospital during the same period, 2011 to 2014. All tissues used were reexamined after hematoxylin and eosin staining by pathologists, before TMA construction using 5-μm-thin section of paraffinembedded cores. The present study was reviewed and approved by the DCUMC Institutional Review Board. Informed consent was received from all participating patients.
Immunohistochemical analysis
Immunohistochemical staining for IER3, FHL2 and MDM2 was performed on the TMA slides. The procedures were carried out using the Bond Polymer Intense Detection System (Leica Microsystems, Mount Waverley, VIC, Australia) according to the manufacturer's instruction with minor modifications as previously described. 51 After image acquisition, the proportion of positive cells was determined by a strong immunostaining intensity of squamous cell carcinoma relative to other morphological regions of the cervix, and the proportion and ISs were determined by a modified Allred scoring method. The PS of less than 1% positive cells was equal to zero, and 1-100% positive cells were scored from 1 to 5 using a 20-percent scale. The IS was scaled from 0 to 3 with the nucleus staining nonspecifically '0', weakly '1', moderately '2' or strongly '3'. For the ROC analysis, the proportion and ISs were then summed to produce total scores of 0-8.
